Companies Seres Therapeutics, Inc.
Seres Therapeutics (MCRB): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Seres Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers10th pct.Of 10 peer CEOs
CEO pay, last three years
- $3,158,336FY2023
- $2,682,007FY2024
- $1,775,549FY2025
CEO total pay was $1,775,549 in fiscal 2025, down from $2,682,007 in fiscal 2024.
FY2025: salary $408,333 · bonus $0 · stock awards $0 · option awards $1,338,870
Executives and directors
Eric Shaff · CEOMarella Thorell · CEOMatthew Henn · PresidentTeresa Young · EVPThomas DesRosier · CEOClaire M. Fraser, Ph.D · Independent DirectorDennis A. Ausiello, M.D · Independent DirectorHans-Juergen Woerle, M.D., Ph.D · Independent DirectorKurt C. Graves · Independent DirectorPaul R. Biondi · Former director (through FY2025)Richard N. Kender · Chair of the BoardRobert Rosiello · Independent DirectorStephen A. Berenson · Independent DirectorWillard H. Dere, M.D · Independent Director
Frequently asked questions
Who was the highest-paid executive at Seres Therapeutics, Inc. in fiscal 2025?
As disclosed, Eric Shaff (Former President and Chief Executive Officer) was the highest-paid executive at Seres Therapeutics, Inc. in fiscal 2025, with total compensation of $1,775,549.
How does Seres Therapeutics, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Eric Shaff's total compensation ranked at the 10th percentile of Seres Therapeutics, Inc.'s disclosed peer group.
How did shareholders vote on Seres Therapeutics, Inc.'s executive compensation?
As disclosed, 84.47% of shareholders supported Seres Therapeutics, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Seres Therapeutics, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Seres Therapeutics, Inc. reported total board compensation of $342,629 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Eric Shaff | $408,333 | $0 | $0 | $1,338,870 | $0 | $0 | $28,346 | $1,775,549 |
| Former President and Chief Executive Officer | ||||||||
| Thomas DesRosier | 512,900 | 166,667 | 0 | 446,290 | 0 | 0 | 10,166 | 1,136,023 |
| Former Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Legal Officer | ||||||||
| Marella Thorell | 494,400 | 166,667 | — | 446,290 | 0 | 0 | 6,039 | 1,113,396 |
| Former Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Financial Officer | ||||||||
| Teresa Young | 489,300 | 0 | 75,682 | 446,290 | 0 | 0 | 10,190 | 1,021,462 |
| Former Executive Vice President and Chief Commercial and Strategy Officer | ||||||||
| Matthew Henn | 489,300 | 0 | 75,682 | 446,290 | 0 | 0 | 3,075 | 1,014,347 |
| President and Chief Scientific Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Eric Shaff | $1,775,549 | $2,682,007 | $3,158,336 | ↓ −906,458 |
| Thomas DesRosier | 1,136,023 | 1,248,507 | — | ↓ −112,484 |
| Marella Thorell | 1,113,396 | — | — | — |
| Teresa Young | 1,021,462 | — | 1,820,458 | — |
| Matthew Henn | 1,014,347 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program has been designed to motivate, reward, attract and retain high caliber management deemed essential to ensure our success. The program seeks to align executive compensation with our short- and long-term objectives, business strategy and financial performance.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards, LLC |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Teresa Young | OPTION | 2025-02-07 | — | — | 32,500 | — | $446,290 |
| Thomas DesRosier | OPTION | 2025-02-07 | — | — | 32,500 | — | 446,290 |
| Teresa Young | RSU | 2025-09-26 | — | — | 3,998 | — | 75,682 |
| Matthew Henn | OPTION | 2025-02-07 | — | — | 32,500 | — | 446,290 |
| Matthew Henn | RSU | 2025-09-26 | — | — | 3,998 | — | 75,682 |
| Eric Shaff | OPTION | 2025-02-07 | — | — | 97,500 | — | 1,338,870 |
| Marella Thorell | OPTION | 2025-02-07 | — | — | 32,500 | — | 446,290 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Teresa Young | $75,682 | $0 | $446,290 | 0.0% |
| Thomas DesRosier | 0 | 0 | 446,290 | 0.0% |
| Matthew Henn | 75,682 | 0 | 446,290 | 0.0% |
| Eric Shaff | 0 | 0 | 1,338,870 | 0.0% |
| Marella Thorell | 0 | 0 | 446,290 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Teresa Young | Option | 375 | 147.6 | — |
| Thomas DesRosier | Option | 407 | 147.6 | — |
| Matthew Henn | Option | 547 | 147.6 | — |
| Thomas DesRosier | RSU | 664 | — | 9,880 |
| Teresa Young | RSU | 664 | — | 9,880 |
| Matthew Henn | RSU | 704 | — | 10,476 |
| Matthew Henn | RSU | 878 | — | 13,065 |
| Teresa Young | RSU | 878 | — | 13,065 |
| Thomas DesRosier | RSU | 1,001 | — | 14,895 |
| Thomas DesRosier | Option | 1,329 | 110 | — |
| Teresa Young | Option | 1,329 | 110 | — |
| Matthew Henn | Option | 1,407 | 110 | — |
| Eric Shaff | Option | 1,563 | 147.6 | — |
| Eric Shaff | RSU | 1,954 | — | 29,076 |
| Eric Shaff | RSU | 2,989 | — | 44,476 |
| Eric Shaff | Option | 3,907 | 110 | — |
| Matthew Henn | Option | 5,274 | 22 | — |
| Teresa Young | Option | 5,274 | 22 | — |
| Thomas DesRosier | Option | 6,012 | 22 | — |
| Thomas DesRosier | Option | 14,395 | 22 | — |
| Matthew Henn | Option | 14,395 | 22 | — |
| Teresa Young | Option | 14,395 | 22 | — |
| Eric Shaff | Option | 17,930 | 22 | — |
| Marella Thorell | Option | 19,688 | 15.75 | — |
| Thomas DesRosier | Option | 32,500 | 15.64 | — |
| Marella Thorell | Option | 32,500 | 15.64 | — |
| Matthew Henn | Option | 32,500 | 15.64 | — |
| Teresa Young | Option | 32,500 | 15.64 | — |
| Eric Shaff | Option | 41,129 | 22 | — |
| Eric Shaff | Option | 97,500 | 15.64 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Stephen A. BerensonIndependent · Audit · Nominating and Corporate Governance (Chair) | $10,000 | $0 | $158,985 | $0 | $0 | $168,985 |
| Claire M. Fraser, Ph.DIndependent · Audit · Nominating and Corporate Governance | 40,000 | 0 | 111,688 | 0 | 0 | 151,688 |
| Robert RosielloIndependent · Compensation and Talent · Newly elected | 21,257 | 0 | 125,858 | 0 | 0 | 147,115 |
| Hans-Juergen Woerle, M.D., Ph.DIndependent · Science and Clinical Development · Newly elected | 47,486 | 0 | 84,876 | 0 | 0 | 132,362 |
| Dennis A. Ausiello, M.DIndependent · Audit · Science and Clinical Development (Chair) | 20,000 | 0 | 111,688 | 0 | 0 | 131,688 |
| Richard N. KenderEmployee director · Board Chair | 72,500 | 0 | 50,875 | — | 0 | 123,375 |
| Willard H. Dere, M.DIndependent · Audit (Chair) · Nominating and Corporate Governance | 62,500 | 0 | 50,875 | 0 | 0 | 113,375 |
| Kurt C. GravesIndependent · Compensation and Talent (Chair) | 37,500 | 0 | 50,875 | 0 | 0 | 88,375 |
| Paul R. BiondiIndependent · Departed during FY | 31,386 | 0 | 50,875 | 0 | 0 | 82,261 |
| Eric D. ShaffEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $342,629 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $342,629 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Seres Therapeutics as a peer
Companies that benchmark against MCRB
4 companies name MCRB as a compensation peer
- AGENUS INCAGENFY2025
- BIOLIFE SOLUTIONS INCBLFSFY2024
- GERON CORPGERNFY2025
- Ginkgo Bioworks Holdings, Inc.DNAFY2025
Each company listed discloses MCRB in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named MCRB in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ENTA Enanta PharmaceuticalsVYGR Voyager TherapeuticsBDTX Black Diamond TherapeuticsACRV Acrivon TherapeuticsAURA Aura BiosciencesASMB Assembly BiosciencesAVIR Atea PharmaceuticalsRGLS Regulus TherapeuticsLRMR Larimar TherapeuticsMRSN Mersana Therapeutics
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Aura Biosciences | 2025 | Elisabet de los Pinos | $645,483 | $1,492,378 | $1,513,293 | $284,013 | $3,956,167 |
| 2 | Larimar Therapeutics | 2025 | Carole Ben-Maimon | 650,000 | 660,860 | 1,889,160 | 0 | 3,526,423 |
| 3 | Atea Pharmaceuticals | 2025 | Jean-Pierre Sommadossi | 703,490 | 1,315,800 | 962,368 | 422,094 | 3,403,752 |
| 4 | Enanta Pharmaceuticals | 2025 | Jay Luly | 803,300 | 128,550 | 1,223,975 | 591,665 | 2,769,548 |
| 5 | Acrivon Therapeutics | 2025 | Peter Blume-Jensen | 709,893 | 0 | 1,592,245 | 410,400 | 2,718,538 |
| 6 | Regulus Therapeutics | 2023 | Joseph Hagan | 615,800 | 88,000 | 1,528,091 | 332,532 | 2,575,123 |
| 7 | Voyager Therapeutics | 2025 | Alfred Sandrock | 674,903 | 611,900 | 843,900 | 361,917 | 2,508,370 |
| 8 | Assembly Biosciences | 2025 | Jason Okazaki | 647,500 | 661,671 | 573,574 | 585,000 | 2,482,987 |
| 9 | Black Diamond Therapeutics | 2025 | Mark Velleca | 667,400 | 189,000 | 1,006,030 | 348,717 | 2,234,919 |
| 10 | Seres Therapeutics, Inc. | 2025 | Eric Shaff | 408,333 | 0 | 1,338,870 | 0 | 1,775,549 |
| 11 | Mersana Therapeutics | 2024 | Martin Huber | 632,500 | 133,635 | 518,044 | 322,575 | 1,613,754 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Seres Therapeutics, Inc. | not disclosed | Options 100 | not disclosed | Alpine Rewards, LLC |
| Acrivon Therapeutics | not disclosed | Option 100 | not disclosed | not disclosed |
| Assembly Biosciences | not disclosed | Options 100 | No | Alpine Rewards, LLC |
| Atea Pharmaceuticals | not disclosed | not disclosed | not disclosed | Aon |
| Aura Biosciences | not disclosed | not disclosed | not disclosed | Pay Governance |
| Black Diamond Therapeutics | 95% | not disclosed | not disclosed | Aon Human Capital Solutions (Aon plc) |
| Enanta Pharmaceuticals | not disclosed | Options 80 · PSU 10 · MSU 10 | No | Alpine Rewards LLC |
| Larimar Therapeutics | not disclosed | Option 75 · RSU 25 | No | Aon |
| Mersana Therapeutics | not disclosed | Option 75 · RSU 25 | not disclosed | Pearl Meyer & Partners, LLC |
| Regulus Therapeutics | not disclosed | not disclosed | No | Aon/Radford |
| Voyager Therapeutics | 97.5% | not disclosed | No | Alpine Rewards, LLC |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-07-08 | 3,374,813 | 620,353 | 121,295 | 84.47% | Passed |
| 2025 | 2025-04-10 | 57,856,004 | 32,505,142 | 405,645 | 64.03% | Passed |
| 2023 | 2023-06-22 | 91,849,150 | 560,885 | 156,604 | 99.39% | Passed |
| 2022 | 2022-06-22 | 70,250,385 | 1,086,657 | 129,116 | 98.48% | Passed |
| 2021 | 2021-06-16 | 73,748,370 | 446,095 | 106,691 | 99.4% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-07-08 | 84.47%a |
| 2025 | 2025-04-10 | 64.03%b |
| 2023 | 2023-06-22 | 99.39%c |
a. Approved under the standard stated in the filing — “Abstentions will have no effect.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes are not considered to be votes cast and, accordingly, will have no effect on the outcome of the vote on this Proposal.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes are not considered to be votes cast and, accordingly, will have no effect on the outcome of the vote on this proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Matthew Henn | See Remarks | 2026-05-15 | A | 238 | — | — | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-05-15 | — | 1,384 | — | — | 4 insiders, 8 accrual rows | ||
| Thomas DesRosier | See Remarks | 2026-05-15 | A | 244 | — | — | Common | Form 4 ↗ |
| Eric D. Shaff | Director | 2026-05-15 | A | 722 | — | — | Common | Form 4 ↗ |
| Kelly Brady | See Remarks | 2026-05-15 | A | 180 | — | — | Common | Form 4 ↗ |
| Kelly Brady | See Remarks | 2026-05-18 | D | 59 | 8 | 444 | Common | Form 4 ↗ |
| Thomas DesRosier | See Remarks | 2026-05-18 | D | 79 | 8 | 595 | Common | Form 4 ↗ |
| Matthew Henn | See Remarks | 2026-05-18 | D | 77 | 8 | 580 | Common | Form 4 ↗ |
| Eric D. Shaff | Director | 2026-05-18 | D | 259 | 8 | 1,950 | Common | Form 4 ↗ |
| Dennis A. Ausiello | Director | 2026-07-01 | A | 7,508 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Rosiello | Director | 2026-07-01 | A | 7,508 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen A. Berenson | Director | 2026-07-01 | A | 7,508 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kelly Brady | See Remarks | 2026-07-08 | A | 18,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Rosiello | Director | 2026-07-08 | A | 6,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Willard H. Dere | Director | 2026-07-08 | A | 6,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Marella Thorell | See Remarks | 2026-07-08 | A | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Claire Fraser | Director | 2026-07-08 | A | 6,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kurt C. Graves | Director | 2026-07-08 | A | 6,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric D. Shaff | Director | 2026-07-08 | A | 6,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard N. Kender | Director | 2026-07-08 | A | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Matthew Henn | See Remarks | 2026-07-08 | A | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen A. Berenson | Director | 2026-07-08 | A | 6,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dennis A. Ausiello | Director | 2026-07-08 | A | 6,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas DesRosier | See Remarks | 2026-07-08 | A | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-08-15 | — | 1,386 | — | — | 4 insiders, 8 accrual rows | ||
| Thomas DesRosier | See Remarks | 2026-08-15 | A | 245 | — | — | Common | Form 4 ↗ |
| Kelly Brady | See Remarks | 2026-08-15 | A | 181 | — | — | Common | Form 4 ↗ |
| Eric D. Shaff | Director | 2026-08-15 | A | 722 | — | — | Common | Form 4 ↗ |
| Matthew Henn | See Remarks | 2026-08-15 | A | 238 | — | — | Common | Form 4 ↗ |
| Thomas DesRosier | See Remarks | 2026-08-17 | D | 82 | 5 | 373 | Common | Form 4 ↗ |
| Matthew Henn | See Remarks | 2026-08-17 | D | 81 | 5 | 369 | Common | Form 4 ↗ |
| Kelly Brady | See Remarks | 2026-08-17 | D | 64 | 5 | 291 | Common | Form 4 ↗ |
| Eric D. Shaff | Director | 2026-08-17 | D | 263 | 5 | 1,197 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 47 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Matthew Henn | See Remarks | 2026-05-15 | A | 238 | — | — | Common | Form 4 ↗ |
| Thomas DesRosier | See Remarks | 2026-05-15 | D | 133 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas DesRosier | See Remarks | 2026-05-15 | A | 244 | — | — | Common | Form 4 ↗ |
| Eric D. Shaff | Director | 2026-05-15 | D | 331 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric D. Shaff | Director | 2026-05-15 | D | 391 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric D. Shaff | Director | 2026-05-15 | A | 722 | — | — | Common | Form 4 ↗ |
| Thomas DesRosier | See Remarks | 2026-05-15 | D | 111 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Matthew Henn | See Remarks | 2026-05-15 | D | 97 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Matthew Henn | See Remarks | 2026-05-15 | D | 141 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kelly Brady | See Remarks | 2026-05-15 | D | 91 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kelly Brady | See Remarks | 2026-05-15 | D | 89 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kelly Brady | See Remarks | 2026-05-15 | A | 180 | — | — | Common | Form 4 ↗ |
| Kelly Brady | See Remarks | 2026-05-18 | D | 59 | 8 | 444 | Common | Form 4 ↗ |
| Thomas DesRosier | See Remarks | 2026-05-18 | D | 79 | 8 | 595 | Common | Form 4 ↗ |
| Matthew Henn | See Remarks | 2026-05-18 | D | 77 | 8 | 580 | Common | Form 4 ↗ |
| Eric D. Shaff | Director | 2026-05-18 | D | 259 | 8 | 1,950 | Common | Form 4 ↗ |
| Dennis A. Ausiello | Director | 2026-07-01 | A | 7,508 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Rosiello | Director | 2026-07-01 | A | 7,508 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen A. Berenson | Director | 2026-07-01 | A | 7,508 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kelly Brady | See Remarks | 2026-07-08 | A | 18,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Rosiello | Director | 2026-07-08 | A | 6,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Willard H. Dere | Director | 2026-07-08 | A | 6,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Marella Thorell | See Remarks | 2026-07-08 | A | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Claire Fraser | Director | 2026-07-08 | A | 6,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kurt C. Graves | Director | 2026-07-08 | A | 6,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric D. Shaff | Director | 2026-07-08 | A | 6,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard N. Kender | Director | 2026-07-08 | A | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Matthew Henn | See Remarks | 2026-07-08 | A | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen A. Berenson | Director | 2026-07-08 | A | 6,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dennis A. Ausiello | Director | 2026-07-08 | A | 6,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas DesRosier | See Remarks | 2026-07-08 | A | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas DesRosier | See Remarks | 2026-08-15 | D | 112 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas DesRosier | See Remarks | 2026-08-15 | D | 133 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas DesRosier | See Remarks | 2026-08-15 | A | 245 | — | — | Common | Form 4 ↗ |
| Eric D. Shaff | Director | 2026-08-15 | D | 332 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kelly Brady | See Remarks | 2026-08-15 | D | 90 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kelly Brady | See Remarks | 2026-08-15 | A | 181 | — | — | Common | Form 4 ↗ |
| Eric D. Shaff | Director | 2026-08-15 | D | 390 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kelly Brady | See Remarks | 2026-08-15 | D | 91 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Matthew Henn | See Remarks | 2026-08-15 | D | 98 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Matthew Henn | See Remarks | 2026-08-15 | D | 140 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric D. Shaff | Director | 2026-08-15 | A | 722 | — | — | Common | Form 4 ↗ |
| Matthew Henn | See Remarks | 2026-08-15 | A | 238 | — | — | Common | Form 4 ↗ |
| Thomas DesRosier | See Remarks | 2026-08-17 | D | 82 | 5 | 373 | Common | Form 4 ↗ |
| Matthew Henn | See Remarks | 2026-08-17 | D | 81 | 5 | 369 | Common | Form 4 ↗ |
| Kelly Brady | See Remarks | 2026-08-17 | D | 64 | 5 | 291 | Common | Form 4 ↗ |
| Eric D. Shaff | Director | 2026-08-17 | D | 263 | 5 | 1,197 | Common | Form 4 ↗ |
Sources (87 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Eric Shaff. DEF 14A, filed 2026-04-27. Section “2025 Summary Compensation Table” · page 41. As printed: 1,775,549. View filing ↗
- Section 01, Thomas DesRosier. DEF 14A, filed 2026-04-27. Section “2025 Summary Compensation Table”. As printed: 1,136,023. View filing ↗
- Section 01, Marella Thorell. DEF 14A, filed 2026-04-27. Section “2025 Summary Compensation Table”. As printed: 1,113,396. View filing ↗
- Section 01, Teresa Young. DEF 14A, filed 2026-04-27. Section “2025 Summary Compensation Table”. As printed: 1,021,462. View filing ↗
- Section 01, Matthew Henn. DEF 14A, filed 2026-04-27. Section “2025 Summary Compensation Table”. As printed: 1,014,347. View filing ↗
- Section 03, Teresa Young OPTION. DEF 14A, filed 2026-04-27. Section “ATTENDANCE BY MEMBERS OF THE BOARD OF DIRECTORS AT MEETINGS” · grants of plan-based awards table. View filing ↗
- Section 03, Thomas DesRosier OPTION. DEF 14A, filed 2026-04-27. Section “ATTENDANCE BY MEMBERS OF THE BOARD OF DIRECTORS AT MEETINGS” · grants of plan-based awards table. View filing ↗
- Section 03, Teresa Young RSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Matthew Henn OPTION. DEF 14A, filed 2026-04-27. Section “ATTENDANCE BY MEMBERS OF THE BOARD OF DIRECTORS AT MEETINGS” · grants of plan-based awards table. View filing ↗
- Section 03, Matthew Henn RSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Eric Shaff OPTION. DEF 14A, filed 2026-04-27. Section “ATTENDANCE BY MEMBERS OF THE BOARD OF DIRECTORS AT MEETINGS” · grants of plan-based awards table. View filing ↗
- Section 03, Marella Thorell OPTION. DEF 14A, filed 2026-04-27. Section “ATTENDANCE BY MEMBERS OF THE BOARD OF DIRECTORS AT MEETINGS” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-12. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Stephen A. Berenson. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 168,985. View filing ↗
- Section 08, Claire M. Fraser, Ph.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 151,688. View filing ↗
- Section 08, Robert Rosiello. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 147,115. View filing ↗
- Section 08, Hans-Juergen Woerle, M.D., Ph.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 132,362. View filing ↗
- Section 08, Dennis A. Ausiello, M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 131,688. View filing ↗
- Section 08, Richard N. Kender. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 123,375. View filing ↗
- Section 08, Willard H. Dere, M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 113,375. View filing ↗
- Section 08, Kurt C. Graves. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 88,375. View filing ↗
- Section 08, Paul R. Biondi. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 82,261. View filing ↗
- Section 08, Eric D. Shaff. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Matthew Henn 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas DesRosier 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas DesRosier 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eric D. Shaff 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eric D. Shaff 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eric D. Shaff 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas DesRosier 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Henn 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Henn 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kelly Brady 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kelly Brady 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kelly Brady 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kelly Brady 2026-05-18. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas DesRosier 2026-05-18. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Henn 2026-05-18. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eric D. Shaff 2026-05-18. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis A. Ausiello 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Rosiello 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen A. Berenson 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kelly Brady 2026-07-08. Form 4, filed 2026-07-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Rosiello 2026-07-08. Form 4, filed 2026-07-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Willard H. Dere 2026-07-08. Form 4, filed 2026-07-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marella Thorell 2026-07-08. Form 4, filed 2026-07-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Claire Fraser 2026-07-08. Form 4, filed 2026-07-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kurt C. Graves 2026-07-08. Form 4, filed 2026-07-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eric D. Shaff 2026-07-08. Form 4, filed 2026-07-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard N. Kender 2026-07-08. Form 4, filed 2026-07-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Henn 2026-07-08. Form 4, filed 2026-07-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen A. Berenson 2026-07-08. Form 4, filed 2026-07-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis A. Ausiello 2026-07-08. Form 4, filed 2026-07-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas DesRosier 2026-07-08. Form 4, filed 2026-07-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas DesRosier 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas DesRosier 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas DesRosier 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eric D. Shaff 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kelly Brady 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kelly Brady 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eric D. Shaff 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kelly Brady 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Henn 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Henn 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eric D. Shaff 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Henn 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas DesRosier 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Henn 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kelly Brady 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eric D. Shaff 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-07-08. Item 5.07 · say-on-pay result. As reported: 84.47% (votes for as printed: 3,374,813). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-04-14. Item 5.07 · say-on-pay result. As reported: 64.03% (votes for as printed: 57,856,004). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-23. Item 5.07 · say-on-pay result. As reported: 99.39% (votes for as printed: 91,849,150). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 342,629 + equity 0 + all other 0 = 342,629, summed across the director compensation table rows.
- Aura Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in Aura Biosciences's own proxy. As printed: 3,956,167. View filing ↗
- Larimar Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in Larimar Therapeutics's own proxy. As printed: 3,526,423. View filing ↗
- Atea Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Atea Pharmaceuticals's own proxy. As printed: 3,403,752. View filing ↗
- Enanta Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-01-26. CEO total compensation as printed in Enanta Pharmaceuticals's own proxy. As printed: 2,769,548. View filing ↗
- Acrivon Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Acrivon Therapeutics's own proxy. As printed: 2,718,538. View filing ↗
- Regulus Therapeutics, Section 10b CEO total. DEF 14A, filed 2024-04-19. CEO total compensation as printed in Regulus Therapeutics's own proxy. As printed: 2,575,123. View filing ↗
- Voyager Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Voyager Therapeutics's own proxy. As printed: 2,508,370. View filing ↗
- Assembly Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Assembly Biosciences's own proxy. As printed: 2,482,987. View filing ↗
- Black Diamond Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Black Diamond Therapeutics's own proxy. As printed: 2,234,919. View filing ↗
- Seres Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Seres Therapeutics, Inc.'s own proxy. As printed: 1,775,549. View filing ↗
- Mersana Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Mersana Therapeutics's own proxy. As printed: 1,613,754. View filing ↗